Both LY2405319 and FGF21 were subsequently shown to exert nearly identical pharmacologic effects when administered to two distinct mouse models of obesity and Type 2 diabetes. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.